India's NPPA brings many more drug formulations under price control
A small notification by Indian drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has ensured that drug formulations under price control have risen to over 800, reports The Pharma Letter’s India correspondent.
The government has brought more medicines, used for the treatment of diseases such as cancer, HIV/AIDS, analgesics and cardiovascular diseases, under its purview.
The Department of Pharmaceuticals has notified an amendment of the Schedule I of Drug Price Control Order (DPCO) 2013, for substituting the National List of Essential Medicines (NLEM) 2011 by NLEM 2015. What this has effectively done is bring on board 200 formulations under the price cap. Under NLEM 2011, there were 628 drug formulations that were under price control.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze